Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
May 27th, 2008
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced more than 40 data presentations at the 2008 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the potential for Nexavar(R) (sorafenib) tablets in multiple tumor types as a single agent or in combination with other agents. "Data at ASCO will expand upon and support the proven efficacy and tolerability of Nexavar in liver cancer and advanced kidney cancer and provide new insight into the potential of Nexavar in additional types of cancer," said Henry Fuchs, MD, executive vice president and chief medical officer of Onyx Pharmaceuticals. "Highlights include...
Source: Cancer Weekly (2008-05-27)
|
